reason report
focus strategi deserv premium initi op pt
bottom line initi coverag azn op rate
pt stock experienc signific appreci
sinc current trade premium versu peer believ
focus strategi establish astrazeneca best-in-class
compani expect momentum continu
astrazeneca success transit gener therapeut
compani rapidli grow oncolog compani number multi-
blockbust drug compani also invest area
rapid growth includ emerg market like gener
addit investor valu area becom commerci
valid relev
astrazeneca transit oncolog focus compani
astrazeneca revenu deriv oncolog
asset major revenu cardioren respiratori
diseas respect forecast
astrazeneca revenu oncolog legaci
cardioren respiratori franchis decreas
total revenu shift toward high margin high growth oncolog
asset forecast improv fundament compani expect
oper margin improv impress
chang despit continu invest heavili sale
similarli shift oncolog allow focus specialti sale forc
support portfolio result effici alloc
sale forecast
revenu annual growth rate bottom line growth
rate result streamlin oper best-in-
class metric deserv premium view
astrazeneca establish strong portfolio oncolog asset
intern extern detail initi believ
astrazeneca establish one strongest oncolog portfolio
pharmaceut industri see segment busi
grow annual rate despit risk
adjust opportun larg start base revenu
grow tagrisso flagship oncolog asset view oral
administ small molecul approv treat lung cancer patient
egfr mutat forecast tagrisso drug global
peak key oncolog asset describ detail
peak trastuzumab deruxtecan peak
astrazeneca well posit off-set neg impact
target agent io address lung cancer market
believ could high patient
assess imfinzi opportun consid potenti impact
target agent io usag lung cancer nsclc mutat like
dcf discount
termin growth rate
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil azn
compani inform svb leerink llc research
revenu ep per adr share
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
egfr ret kra braf may
impact number patient receiv cpi inhibit especi
front-lin importantli astrazeneca tagrisso posit compani
off-set potenti loss address io opportun describ
report
respiratori cardioren metabol franchis modest
growth rel oncolog portfolio forecast modest growth
respiratori franchis annual driven
recent approv fasenra pulmicort uptak ex-u off-set
symbicort declin overal expect respiratori franchis revenu
contribut declin revenu
similarli expect cardioren metabol franchis experi
annual growth driven roxadustat peak
lokelma peak brilinta peak offset declin
metabol franchis term rel revenu contribut
forecast cardioren metabol franchis declin
invest emerg market core part compani
strategi astrazeneca continu invest emerg market
emerg market repres report sale
percentag increas forecast
compound annual growth rate emerg market sale
particularli strong presenc china includ
employe see astrazeneca well-posit benefit
increasingli import region
oncolog focu lead improv fundament
assess shift oncolog focu lead improv
fundament compani oncolog asset typic higher
profit margin less subject price restrict competit
payor leverag forecast azn oper margin improv
view compani abil
grow margin despit spend significantli signific
price target repres assess discount cash
flow pt repres core earnings/adr
higher peer azn appreci consider sinc
believ compani well-posit continu deliv
initi coverag astrazeneca outperform rate price target
astrazeneca global biopharmaceut compani success transit
compani focus primarili therapeut treat gener medic condit one
driven oncolog portfolio expect grow compound annual growth rate
thru forecast report oncolog revenu exceed total revenu
compani time proport strateg chang result
compani global reach leverag develop promot multipl drug
mutli-blockbust potenti high margin long period exclus best-in-class statu
shift toward target approach allow astrazeneca becom streamlin
regard oper expens view astrazeneca portfolio unparallel larg
pharmaceut univers term innov anticip growth mani asset
develop intern compani also engag extern acquisit bolster
pipelin well strateg collabor deem prudent furthermor compani
also invest infrastructur geograph area high growth like china
still demand legaci asset well new product see section emerg market
china forecast astrazeneca report sale emerg market
anticip annual growth
forecast astrazeneca oncolog revenu doubl account
astrazeneca product sale oncolog portfolio commerci
asset includ two drug consid best-in-class/market leader tagrisso egfr inhibitor
lynparza parp inhibitor well burgeon multi-blockbust product like imfinzi
calquenc near-term see trastuzumab deruxtecan promis
oncolog pipelin asset forecast peak revenu tumor econom
split partner daiichi sankyo revenu oncolog asset
major total deriv product focus respiratori cardio/metabol
diseas view oncolog sector repres desir area invest
pharmaceut arena given high unmet medic need surg innov
molecular genet driver diseas better understood intervent
becom precis base price power like larg inelast less direct
competit payor leverag lead higher margin note therapeut area
view tagrisso flagship astrazeneca asset sale
higher consensu view tagrisso astrazeneca flagship oncolog asset
gener revenu usag egfr mutat lung cancer forecast
compound annual growth rate egfr mutat found
lung cancer nsclc rate vari geographi genet smoke histori
drug third gener oral administ tyrosin kinas inhibitor egfr activ
primari egfr mutat exon exon well resist mutat
caus failur earlier gener egfr inhibitor mutat
high activ wild type mutat acquir resist mutat drug
demonstr unpreced efficaci see clinic trial data section front-lin drug well
patient fail egfr agent astrazeneca plan move drug earlier stage
lung cancer success could expand market opportun significantli tagrisso
exclus forese near-term competit drug
lynparza market lead parp inhibitor estim forecast sale
lynparza oral drug leverag preval dna repair
defici cancer cell caus tumor regress drug approv mainten
agent multipl line therapi ovarian cancer well treatment metastat breast
cancer anticip approv treatment prostat cancer forecast
world-wide sale drug grow rate annual
current approv parp inhibitor us europ astrazeneca partner merck
op establish drug market leader combin market
expertis strateg trial design expect drug remain market leader
tumor type potenti expans tumor like pancreat bladder lung
astrazeneca partner merck test drug monotherapi combin
number agent medacorp kol continu see lynparza domin
parp inhibitor loss exclus model
imfinzi despit cpi market success creat safe harbor stage
lung cancer peak sale possibl across indic
estim astrazeneca checkpoint inhibitor cpi imfinzi higher consensu
driven primarili preferenti usag patient stage lung cancer
surgic resect see safe harbor signific opportun repres
patient us medacorp kol indic imfinzi like maintain nich
despit merck keytruda approv stage lung cancer believ qualifi
label patient candid chemoradiotherapi signific commerci
disadvantag given current treatment paradigm support chemoradiotherapi
set importantli imfinzi label use chemoradiotherapi view use cpi
radiotherapi scientif rational like increas activ cpi increas
tumor inflamm perfus antigen cell death contrast keytruda label use
stage candid candid chemoradiotherapi could preclud
uptak set forecast think imfinzi minor share
indic like bladder cancer small cell lung cancer head neck cancer given
competit agent first-mov advantag also assign minim valu
compani drug tremelimumab see drug incorpor
io treatment paradigm whether gain approv regulatori agenc point
clear us agent offer signific advantag chemotherapi regimen
calquenc like becom multi-blockbust drug offer imbruvica patient
toler issu altern imbruvica oral administ btk inhibitor
transform treatment b-cell malign like cll offer unpreced efficaci cll
patient take imbruvica often outliv diseas die caus malign
imbruvica gener annual sale op partner johnson
johnson op although imbruvica emerg signific commerci clinic
success patient develop toler issu bleed atrial fibril
requir discontinu btk inhibitor despit remiss calquenc
select btk inhibitor demonstr lower rate atrial fibril bleed
imbruvica offer imbruvica patient toler issu option remain btk rather
switch class drug inde despit initi approv small indic mantl
cell lymphoma mcl drug compendium nccn treatment guidelin list r/r
chronic lymphocyt lymphoma cll astrazeneca recent suggest compani
earn call revenu deriv cll despit yet
offici label calquenc label expans us approv novemb ad
treatment nave frontlin relapsed/refractori cll languag data label data
contain label phase elevate-tn ascend trial gener in-lin
expect suggest calquenc favor safety/toler profil
rel imbruvica view calquenc signific player btk inhibitor market
despit anticip competit beigen bgne op brukinsa zanubrutinib
recent receiv fda approv r/r mcl forecast calquenc sale grow annual
anticip growth continu beyond forecast year gener loe
see trastuzumab deruxtecan promis near-term oncolog
pipelin drug peak world-wide sale astrazeneca sign collabor
agreement daiichi sankyo march add next-gener antibodi drug
conjug oncolog portfolio term deal includ cost
profit split world-wide right exclud japan describ section
report drug construct antibodi receptor connect
payload high drug antibodi ratio drug highli membran
permeabl allow kill neighbor cell tumor may vari level
express data date superl show unpreced efficaci
heavily-pretr patient well activ intermedi low express
tumor addit drug demonstr impress efficaci gastric cancer
patient well nsclc patient forecast peak world-wide sale
major sale come metastat breast cancer mbc
importantli complex molecul featur antibodi drug date
approv biosimilar/gener pathway agent suggest ip
like extrem long runway beyond forecast horizon
beyond oncolog view roxadustat promis drug patient anemia
renal diseas myelodysplast syndrom md compani collabor
op joint develop commerci roxadustat oral
administ hif agent increas red cell product induc hypoxia axi drug
develop anemia relat renal diseas myelodysplast syndrom md
renal arena drug compet esa drug use replac decreas
erythropoietin hallmark patient current forecast peak sale
compound annual growth rate
dialysi esrd broadli think largest opportun dialysi set
major patient administ intraven erythropoietin stimul agent esa
dialysi procedur forecast opportun worth peak
 take account commerci success dialysi set complic
especi us dialysi drug reimburs bundl strategi
larg chain dialysi chain control market dynam think hif drug class
could captur dialysi market depend patient treatment set
addit dialysi set patient adequ respond esa
hyporespond nich hif drug could preferenti captur
ckd patient dialysi chronic kidney diseas ckd set see largest
opportun patient alreadi esa drug less high
risk transfus model depend stage renal insuffici see
conserv uptak largest ckd opportun esa nave patient risk
transfus conservat area result evolv treatment paradigm
anemia manag ckd set current reserv esa usag patient
risk blood transfus possibl astrazeneca could success chang
anemia treatment paradigm ckd leverag data suggest hif usag delay
progress renal insuffici baselin forecast assum shift
md encourag preliminari roxadustat data date md myeloprolif
disord mark signific anemia data dose-rang trial present
american societi hematolog dec abstract suggest drug
signific impact red cell product risk transfus importantli drug
price esa level could captur signific portion current esa off-label usag
expect modest growth legaci respiratori cardioren franchis histor
cardioren respiratori franchis focu astrazeneca repres
compani product sale respect franchis includ blockbust
product crestor statin hypercholesterolemia pulmicort asthma
astrazeneca focu shift oncolog forecast modest growth respiratori
franchis annual driven recent approv fasenra well
pulmicort/symbicort sale ex-u forecast respiratori franchis contribut azn
revenu declin similarli expect cardioren
cvrm franchis grow annual driven roxadustat hif anemia
peak sale lokelma potassium binder peak sale brilinta antiplatelet
peak sale offset declin legaci diabet hypercholesterolemia
franchis forecast cardioren franchis repres azn product sale
emerg market provid geograph diversif extend tail product
end exclus western market astrazeneca invest heavili
build chines infrastructur forecast product revenu emerg market increas
combin launch new drug region well
obtain reimburs nation formulari nrdl commerci infrastructur
china also allow compani conduct trial region effici leverag high
diseas preval speed time approv china potenti global astrazeneca
also focus emerg market outsid china sourc expans
diversif pleas see section emerg market report detail forecast
diversif away legaci franchis toward oncolog result
impress revenu growth improv margin earn despit increas
expens addit drive impress revenu growth astrazeneca focu oncolog
drug like streamlin compani expens translat bottom line improv
margin ep see gross margin increas
forecast compani core earnings/adr reach result
ep compound-annual-growth-rate forecast impress bottom line growth despit higher
expens support pipelin continu innov despit higher expens
larg pharma peer sale like formula suggest higher probabl
success growth continu futur
uniqu astrazeneca rich pipelin catalyst ensur news flow investor
engag view astrazeneca impress calendar upcom meaning
catalyst exist commerci product well pipelin drug list
key catalyst see next month
near-term key potenti catalyst azn clinic data present medic
meet includ phase data roxadustat american societi hematolog
annual meet oral present decemb data trastuzumab
deruxtecan phase trial metastat breast cancer
oral present decemb san antonio breast cancer symposium sabc
anoth potenti catalyst expect includ top-line data beigen phase
aspen trial evalu brukinsa zanubrutinib head-to-head vs imbruvica waldenstrom
could meaning read-through astrazeneca compet btk inhibitor calquenc
companyprogram/drugtherapeut areaeventtimingev typetri phaseazn/fgenroxadustatmd anemia phase data roxadustat mds-relat anemia trial breast cancerphas trial trastuzumab deruxtecan data metastat breast cancer trial dataphiiiazn/mrklynparzapancreat cancerfda decis lynparza brcam pancreat cancer aspen trial brukinsa r/r waldenstrom macroglobulinemia vs trial gastric cancerphas data trastuzumab deruxtecan gastric trial dataphiiastrazenecaimfinzibladd cancerdata phase danub imfinzi treme/imfinzi/soc bladder trial dataphiiiastrazenecaimfinzihead neck cancerphas kestrel data imfinzi/ imfinzi treme/ soc head neck trial dataphiiiastrazenecabrilintastrokephas thale brilinta vs placebo acut ischaem stroke transient ischaem clinic trial dataphiiiazn/mrkselumetinibpediatr approv selumetinib pediatr neurofibromatosi type pdufa date breast cancerpotenti approv metastat breast surviv data phase poseidon trial trial dataphiiiastrazenecaimfinzinsclcpotenti regulatori submission/accept poseidon trial aegean imfinzi chemo data neoadjuv stage resect nsclc trial dataphiiiastrazenecaimfinzinsclcphas imfinzi chemort vs placebo chemort data unresect locally-advanc trial dataphiiiastrazenecaepanovahypertriglyceridaemiaphas strength data epanova statin patient hypertriglyceridaemia high cardiovascular increas risk trial denali mild moder trial dataphiiiastrazenecafasenraasthmaphas meltemi ponent trial asthmat adult ic plu agonist trial dataphiiiastrazenecafasenranas polyposisdata phase ostro sever bilater nasal trial dataphiiiastrazenecatezepelumabasthmadata phase navig trial sever trial nsclcphase data trastuzumab deruxtecan mutat trial dataphiiiastrazenecaimfinzi tremensclcdata phiii poseidon trial nsclc imfinzi chemo vs imfinzi treme chemo vs chemo trial dataphiiiclovi oncologyrubracaovarian cancerdata phiii athena studi rubraca/opdivo ovarian cancer mainten per compani trial dataphiiikey near-term astrazeneca catalyst astrazeneca plc
valuat methodolog valu astrazeneca azn per base result
discount cash flow dcf analysi contempl free cash flow forecast
assum termin growth rate weight averag cost capit wacc
sensit analysi show chang termin growth rate wacc
assumpt yield /- chang fair valu estim respect
risk valuat
 clinic trial risk astrazeneca numer late-stag clinic asset includ
trastuzumab deruxtecan roxadustat well sever approv product meaning
label expans opportun depend success clinic trial includ imfinzi lynparza
calquenc clinic trial failur late-stag clinic asset repres risk current
 regulatori risk even posit clinic trial result market author requir approv
regul variou jurisdict regulatori delay reject applic key
pipelin product would repres risk current valuat
 competit risk astrazeneca market product competit therapeut area includ
oncolog renal/cardiovascular respiratori competit could lead azn product sale
materi estim repres risk current price target
 price reimburs legisl affect drug price includ propos legisl
 could link drug price intern benchmark risk commerci
tagrisso egfr flagship azn oncolog portfolio
epiderm growth factor receptor egfr mutat occur lung cancer rate
vari geograph associ smoke statu differ mutat
egfr kinas domain identifi lung cancer patient harbor primari
egfr-mut exon delet account primari egfr
mutat typic egfr tyrosin kinas inhibitor tki recommend first-lin
therapi egfr-mut nsclc rel high rate clinic respons
howev patient typic acquir resist tki median
follow first second-gener approv egfr inhibitor market estim
patient develop resist mechan common
resist mechan occur approxim egfr-mut nsclc patient
mutat also driven develop next gener kinas inhibitor
tagrisso target egfr tki-sensit mutat resist mutat current
tagrisso drug approv overcom resist mechan
exhibit frequenc molecular aberr driver oncogen lung cancer
exhibit egfr-mut posit advanc nsclc treat tki
tagrisso rapidli becom prefer regimen second line given differenti
activ mutat given limit treatment option patient develop
mutat robust data trial tagrisso initi approv second
line therapi patient develop mutat post frontlin egfr tki treatment
trial durat median significantli longer tagrisso group platinum-
pemetrex group vs hr respons rate durat respons also
favor tagrisso vs platinum-pemetrex group show vs orr vs
respect subgroup posit tumor plasma patient also
show significantli longer platinum-pemetrex vs hr
orr significantli better tagrisso group platinum-pemetrex group vs
regimentri median month mdor month respons rategefitinib vs lux-lung archer vs chemo eurtac optim vs gefitinib lux-lung lux-lung lux-lung dacomitinib vs gefitinib archer vs vs vs osimertinib vs chemo aura vs vs vs osimertinib vs gefitinib erlotinib vs vs vs astrazeneca plc
exhibit tagrisso treat mutat patient
abil preempt mutat extend durabl respons delay
progress frontlin make tagrisso drug choic
phase flaura trial landmark success azn tagrisso compar tagrisso
monotherapi iressa gefitinib tarceva erlotinib monotherapi frontlin set
object respons rate proport patient tumor shrinkag
show statist differ group vs overal cohort measur
much longer time progress respond measur
durat respons dor month tagrisso group month
standard tki gefitinib erlotinib durat respons tagrisso
significantli longer standard egfr-tki vs base data
fda approv frontlin usag tagrisso april ema approv grant june
china follow label expans septemb
exhibit tagrisso show benefit frontlin egfr mutat nsclc patient
overal surviv benefit also note tagrisso frontlin usag reaffirm drug
standard care line egfr mutat nsclc final updat data present
vs hr overal popul definit establish tagrisso
drug choic frontlin egfr mutat lung cancer os
month also higher compar
respect treatment tagrisso also delay time first subsequ treatment
death compar iressa gefitinib tarceva erlotinib vs month hr
note subgroup stratifi surviv analysi tagrisso appear surviv benefit
asian patient hr show surviv benefit non-asian patient hr
gener egfr inhibitor shown efficaci asian patient like rais
bar statist improv expect regulatori agenc supplement label
os data unclear whether less definit impact os asian patient
referenc label see distinct commerci relev overal
see robust data support tagrisso standard-of-car frontlin
exhibit tagrisso overal surviv flaura trial
compani present esmo
tagrisso also benefici patient metastasi signific problem
patient phase bloom trial present tagrisso show leptomening
metastas lm respons evalu patient investig assess
median durat respons month follow median durat drug exposur
month trial subgroup patient metastas show longer
tagrisso compar platinum-pemetrex month vs month separ
frontlin treatment tagrisso also demonstr longer gefitinib erlotinib month
vs month hr flaura trial updat flaura studi esmo tagrisso
also show statist signific reduct risk diseas progress
increas time patient met live without diseas progress death
reach vs hr estim egfr mutant nsclc patient
develop metastasi make tagrisso activ clinic commerci relev
exhibit tagrisso patient metastas trial
laura trial may bring tagrisso stage set similar imfinzi
tagrisso evalu monotherapi phase laura trial follow chemoradi
patient stage unresect egfrm nsclc like establish treatment imfinzi
pacif base medacorp kol feedback diagnosi rate egfr earlier stage
nsclc low especi non-smok patient rate like ramp tagrisso
target agent show clinic benefit non-metastat set given
unpreced efficaci egfr mutat metastat set expect laura could read
posit potenti expand tagrisso earlier stage nsclc also expect posit
laura trial could potenti shift treatment paradigm portion egfrm patient might
treat tagrisso instead establish standard care imfinzi regimen imfinzi
show benefit egfr mutat posit nsclc small group believ tagrisso
potenti benefit hr ratio direct compar imfinzi estim
see peak valu us world-wide non-metastat set
on-going clinic studi mainten adjuv set surgeri well
combin trial nsclc expand franchis establish tagrisso backbon
therapi azn initi pivot adaura trial evalu tagrisso adjuv
egfrm nsclc set primari endpoint disease-fre surviv anticip
combin regimen evalu expand treatabl patient phase
trial tagrisso combin chemo expand frontlin patient pool expect
increas diagnosi rate due develop oncogen mutat driver kra
ntrk other could increas panel diagnosi rate potenti ad
patient tagrisso pool tagrisso show robust clinic activ patient
inevit develop secondari resist treatment pose signific challeng due
lack therapeut option avail date phase savannah trial combin
tagrisso savolitinib inhibitor evalu potenti resist mechan aris
amplif post tagrisso treatment
forecast tagrisso primari growth engin oncolog product portfolio
peak sale compound-annual-growth-rate
follow tagrisso first line approv us base flaura trial tagrisso becom
domin drug egfr mutat nsclc global sale tagrisso reach
impress growth yoy estim tagrisso global peak sale exceed
consensu expect believ strong
uptak occur global includ emerg market china establish row
market japan current azn estim tagrisso sale us japan
patient receiv drug frontlin set eu adopt robust
although azn estim sale frontlin set reimburs
pend key market azn also indic strong frontlin launch china aid
placement china nation reimburs drug list nrdl net price
us list price medacorp kol expect tagrisso continu domin frontlin
increas avail next gener sequenc drive penetr global
svb leerink research compani report
lynparza establish best-in-class parp
lynparza unexpectedli grant broad label ovarian cancer allow drug rapidli
domin parp class opinion one critic inflexion point parp market
occur lynparza unexpectedli grant broad label mainten
set allow drug prescrib all-com irrespect brca statu
competitor tesaro acquir gsk conduct phase zejula trial all-
comer astrazeneca phase trial limit brca patient despit previous
deni mainten label astrazeneca base phase trial studi
includ non-brca patient fda grant astrazeneca request broad label upon
submiss data supplement studi unexpect outcom allow
astrazeneca merck posit lynparza equal foot zejula eventu
cloviss mp rubraca given similar label importantli astrazeneca abl
leverag well-establish global footprint lynparza captur major market
share ovarian cancer lynparza current share parp inhibitor revenu
global estim lynparza share ovarian cancer revenu approxim
exhibit lynparza trial ovarian cancer mainten
lynparza move frontlin ovarian cancer brca set recent follow
unexpect broad approv lynparza second-lin drug advanc frontlin
brca-mut ovarian cancer base trial demonstr statist
signific improv lynparza vs placebo median lynparza arm
reach chemotherapi month risk diseas
progress death lower lynparza placebo median time first
subsequ therapi death lynparza group vs placebo group
data overal surviv matur assess lynparza show surviv benefit
practic pattern paola trial may render gsk prima trial advantag less import
outer year frontlin label lynparza limit brca patient competitor
gsk prima trial success all-com distinct may less immedi relev
anticip given role avastin set well current practic pattern
establish market avastin usag treatment agent platinum chemotherapi
mainten drug chemo becom standard care frontlin base
medacorp kol input believ ovarian cancer patient us given
avastin frontlin set outsid us rate exce trial
success clinician option includ parp mainten patient test
brca base blood test importantli homolog recombin defici hrd test
wide implement cost requir tumor biopsi data
set made test clinic relev given broad label parp
set therefor hrd statu patient unlik establish
clinic decis whether administ parp frontlin well parp
base primarili blood brca test result see prima trial less relev
clinician adopt broad parp usag frontlin instead current standard care
avastin near-term believ clinician continu use parp drug
choic regard clinician may weigh efficaci data brca patient
suggest lynparza appear numer superior median zejula
month versu lynparza median
brca patient reach
exhibit azn trial lynparza brca patient
exhibit glaxosmithklin prima trial zejula brca patient
zejula domin front-lin may import outer year patient
brca- clinician decid whether administ parp avastin parp plu
avastin opinion think lynparza plu avastin combin unlik broadli
adopt sinc data paola suggest benefit avastin alon
see hrd test broadli implement detect patient hrd point
importantli base paola data clinician may view see benefit expos
patient regimen versu potenti side effect eventu better hrd test may
discov date ovarian cancer benefit test justifi clinic
relev view
exhibit paola trial lynparza/avastin hrd-neg patient
evolv front-lin treatment paradigm see therefor think patient
brca- clinician weigh whether give zejula mainten drug
chemo continu use avastin becom standard care region
decis base primarili clinician anecdot experi drug well
patient toler profil therefor see parp adopt brca- cohort primarili
impact clinician willing abandon avastin current standard care broad
chang treatment paradigm often take time adopt therefor view lynparza
lead parp front-lin ovarian cancer zejula start captur
brca- patient avastin widespread adopt non-tumor base hrd diagnost could
chang dynam render hrd distinct commerci relev
lynparza posit becom domin parp prostat cancer
prostat cancer anoth area parp class posit relev least
patient express degre repair defici data date
compel brca patient subgroup less robust howev lynparza
posit potenti broadest label indic grant label reflect
inclus criteria profound trial trial astrazeneca includ
patient well atm patient anoth key featur trial data suggest
superior xtandi zytiga could help posit drug treatment choic
potenti earlier line therapi
strong profound data support mcrpc regulatori path enabl broader label earlier
line therapi
data random phase profound trial show treatment lynparza
significantli extend radiograph vs anti-androgen hormon agent xtandi zytiga
mcrpc patient brca atm mutat progress prior treatment anti-
analys suggest major benefit driven patient mutat
rpf vs less robust benefit seen patient atm mutat rpf
vs due trial design combin brca atm mutat patient
singl cohort evalu believ possibl lynparza grant label includ
patient popul potenti allow broader use beyond expect
competitor rubraca mp like limit brca patient initi zejula data
mcrpc data galahad trial also show orr recist-evalu brca
patient median rpf month data appear competit though program
behind lynparza rubraca program less clariti regulatori path lynparza
rubraca track submit snda believ lynparza random data
like lead preferenti uptak reimburs particularli europ value-
base govern payor shown prefer random data vs single-arm studi
exhibit lynparza patient brca atm alter profound
exhibit subgroup analys profound suggest benefit driven pt
azn also advanc lynparza frontlin therapi mcrpc employ combin
strategi zytiga global propel trial competitor merg space merck
evalu trial keytruda lynparza vs xtandi zytiga also
conduct pivot trial evalu talzenna xtandi vs xtandi line
exhibit parp inhibitor mcrpc
clovi rubraca could grant approv ahead lynparza mcrpc base singl
arm respons rate data believ lynparza like broadest label
support random data vs anti-androgen agent possibl clovi could gain
acceler approv ahead astrazeneca us base single-arm respons rate
gener studi view data present date
support approv especi sinc fda grant rubraca breakthrough therapi
design btd categori reserv drug data suggest superior
avail standard care area high unmet medic need clovi guidanc suggest
regulatori submiss rubraca label expans expect year end put drug
potenti ahead astrazeneca
drug lynparza olaparib lynparza olaparib rubraca rucaparib zejula xtandi zytigasingl agentsingl agent singl agent brca/hrd statusup gene hrr pathwaybrca atm brca atm otherbrca non-brca fanca atm prior trxar agentsar agent chemo ar agent chemoar agent chemo brca brca month astrazeneca plc
exhibit clovi rubraca efficaci pivot trial mcrpc
lynparza like remain parp choic breast cancer
lynparza first approv parp inhibitor advanced/metastat germlin
brca breast cancer base phase olympiad trial pfizer talzenna also approv
set base phase embraca trial agent demonstr benefit
physician choic chemotherapi median benefit chemo
hazard ratio respect veliparib combin chemotherapi agent
carboplatin /paclitaxel also show benefit hr placebo plu
chemotherapi phase trial howev treatment benefit achiev
combin could greatli limit veliparib clinic use approv
exhibit parp gbrca breast cancer
opinion lynparza like remain parp choic breast cancer given
favor toler profil versu pfizer talzenna signific parp trap
longer dna engag lead chemotherapy-lik toxic includ alopecia complet
hair loss medacorp clinician express concern extens parp
trap could lead secondari malign prevent normal cell repair dna
break mutat
exhibit pfizer talzenna embraca trial
lynparza could first parp access adjuv brcam breast cancer opportun
lynparza current evalu adjuv brca mutat breast cancer patient phase
olympia trial data anticip adjuv breast cancer repres signific
opportun given widespread adopt aggress screen develop countri
lynparza parp inhibitor run adjuv trial estim adjuv
opportun could gener peak revenu bn
pancreat cancer anoth opportun although magnitud benefit much
pancreat cancer lethal condit poor outcom increas incid
standard-of-car pancreat cancer folfinox gemcitabin nab-paclitaxel
median month median os month pancreat cancer
patient harbor germlin mutat mainten treatment delay diseas
progress follow soc care becom key factor treatment pancreat cancer
esmo astrazeneca present polo trial frontlin pancreat cancer patient
germlin brca mutat data show statistically-signific benefit
approxim patient treat lynparza remain progress free year vs
patient receiv placebo blind independ central review plan
interim analysi overal surviv data matur show signific differ overal
surviv lynparza placebo group vs hr lynparza safeti
profil pancreat cancer consist prior drug profil supplement new drug
applic packag fda ema accept expect favor
regulatori decis
exhibit lynparza brca pancreat cancer
astrazeneca merck collabor lynparza strateg direct expans
includ combin io azn merck establish collabor jointli
develop commerci lynparza across sever tumor type includ breast prostat
pancreat cancer collabor also involv parp plu io strategi although
view data date larg disappoint sign synergist activ especi
rel class drug like adc hypothet reason combin includ
activ sting pathway well parp induct neoantigen
lynparza io combin trial watch includ duo-o phase lynparza imfinzi
advanc ovarian cancer bayou phase lynparza imfinzi vs imfinzi stage iv
frontlin cis-platinum chemotherapy-inelig bladder cancer mediola phase i/ii
lynparza imfinzi ovarian breast cancer
exhibit lynparza clinic develop monotherapi combin
imfinzi io franchis
imfinzi play import part astrazeneca oncolog portfolio despit global
imfinzi approv unresect stage nsclc indic form
backbon imfinzi lung cancer revenu drug achiev signific success
nich littl competit cpi expect drug maintain domin
indic forecast revenu peak
estim imfinzi consid impact target agent adopt lung cancer
could impact io opportun much outer year lung cancer
uniqu tumor type respond target agent well io base
data date well clinician input believ tumor oncogen driver like
preferenti treat target agent mutat medacorp kol indic
io option line therapi especi target agent treat acquir
mutat develop mutat like respond io
intervent combin strategi test clinic
model account differ well diagnost test rate
increas time collect model preval diagnosi rate known oncogen
driver mutat lung cancer egfr ret kra braf
also assum forecast period oncogen driver target discov
base clinic data date medacorp kol input make follow broad
assumpt assum usag combin io
assum sequenti usag option
follow graph depict assess net impact target agent could
curtail usag checkpoint
exhibit us model impact oncogen driver i/o address nsclc
exhibit us model impact oncogen driver i/o address nsclc
forecast also consid impact oncogen mutat could impact io
usag tumor oncogen driver still respond io therapi earli
data suggest potenti synergi tumor type io could use downstream
target agent potenti combin therapi clinic data show benefit
follow graph forecast preval driver mutat
exhibit us model diagnos biomark impact nsclc opportun includ
pacif trial creat safe harbor imfinzi
pacif trial establish imfinzi standard care unresect stage nsclc
specif imfinzi approv patient unresect stage nsclc complet
least cycl concurr chemotherapi radiat therapi crt mechanist
believ exposur chemotherapi radiat creat antigen cell death magnifi
inflammatori respons tumor perfus result better respons cpi importantli
imfinzi establish drug choic area statu medacorp kol
expect continu merck approv label stage indic patient
candid chemoradi clinic commerci disadvantag
view given role chemoradi patient well synergist effect
describ
exhibit pacif regimen mechan action
pacif trial improv median significantli patient treat imfinzi vs
placebo vs hr prolong benefit appear seen
across express statu egfr mutat statu patient receiv either cisplatin
carboplatin show similar benefit safeti profil imfinzi consist
immunotherapi prior known safeti profil pacif trial show import
clinic safeti differ imfinzi placebo arm show grade
advers event imfinzi placebo respect antonia engl
discontinu due advers event imfinzi group placebo mainli
due pneumon radiat pneumon grade pneumonitis/radi pneumon
imfinzi placebo respect patient-report outcom
one secondari endpoint also indic clinic benefit achiev without
compromis patient qualiti life hui lancet oncol overal data suggest
imfinzi manag side effect chemoradiotherapi
american societi clinic oncolog azn provid three-year os updat
pacif trial updat os patient consist prior data imfinzi
median os reach rang placebo month median os
show vs placebo
respect manag comment indic better outcom achiev earli
treatment imfinzi post crt durat treatment remain key commerci lever
current assum month treatment durat set
poseidon trial success metastat nsclc extrem competit arena
see metastat nsclc anoth opportun imfinzi though acknowledg
highli competit frontlin treatment bar establish keytruda recent astrazeneca
announc top-line result poseidon trial show statist signific
benefit patient treat combin imfinzi chemo vs chemo alon accord
press releas tripl combin imfinzi plu treme astrazeneca agent
chemo also show statist signific vs chemo alon secondari endpoint
mark poseidon first success trial combin imfinzi tremelimumab howev
rel benefit doublet triplet regimen disclos date
medacorp kol express skeptic like play signific role
nsclc top-line data releas indic triplet regimen could play certain role
subgroup patient squamou diseas given favor safeti profil seen trial
matur os data expect present full dataset venu
determin model view metastat nsclc set blockbust statu
forecast also consid impact target agent opportun
cpi remain cautiou treme add-on effect imfinzi chemo await clear
data detail poseidon present azn indic triplet regimen show
similar safeti profil versu doublet without discontinu
compani report svb leerink research
exhibit us imfinzi revenu estim metastat nsclc
compani report svb leerink research
bladder cancer indic competit durat usag limit commerci
bladder cancer opportun competit arena multipl agent imfinzi one
approv agent bladder cancer patient post chemotherapi
current assum minim imfinzi sale indic respons rate approv pd-
agent rang cisplatin-elig urotheli cancer patient post
chemotherapi on-going imfinzi trial bladder cancer focus earlier line therapi
well adjuv set imfinzi evalu combin tremelizumab phase
danub trial plu tremelizumab chemo phase nile trial bladder cancer
imfinzi also evalu combin gemcitabin cisplatin neoadjuv
treatment follow imfinzi alon adjuv treatment muscle-invas bladder cancer mibc
niagara trial given competit bladder cancer well limit durat
usag less imfinzi bladder revenu forecast
exhibit multipl agent bladder cancer
compani report svb leerink research
caspian trial could add import indic extens sclc tecentriq
approv alreadi keytruda data expect immin
first-lin treatment patient extensive-stag small-cel lung cancer sclc
histor etoposid platinum- ep base chemotherapi tecentriq combin
carboplatin etoposid approv base respons rate
ep chemotherapi rang farago transl lung cancer reflect
clinic observ mani sclc highli sensit platinum/etoposid first-lin
set result often first choic manag patient symptomat diseas
ad tecentriq ep regimen modestli prolong progression-fre surviv vs ep median
vs well extend surviv benefit vs
azn present phase caspian trial evalu imfinzi without tremelimumab plu
ep es-sclc wclc imfinzi ep treat cycl follow imfinzi
trialssudi imvigor cohort drug durvalumabnivolumabpembrolizumabcontrolavelumab atezolizumab median prior overal surviv wk durat respons nrnr durat follow-up astrazeneca plc
monotherapi diseas progress data show overal surviv benefit imfinzi ep
vs ep vs hr line approv therapi tecentriq chemo
hr os month vs os month
vs imfinzi ep vs ep os benefit appear similar across differ
subgroup clinic benefit respons rate month favor
imfinzi ep interestingli imfinzi appear better activ brain met vs tecentriq shown
studi caveat rel small number patient trial
medacorp kol believ imfinzi could offer benefit tecentriq given dose flexibl
data read expect set current
model opportun imfinzi set
exhibit caspian trial overal surviv left progress free surviv right
exhibit caspian trial forest plot overal surviv popul
calquenc hematolog
calquenc next-gener btk inhibitor offer better safeti toler versu
imbruvica calquenc initi approv treatment r/r mcl rel
small indic aggreg sale calquenc sinc launch
reflect off-label usag cll support recent nation comprehens cancer
network nccn practic guidelin list categori recommend r/r cll one
key commerci attribut calquenc could better safeti toler profil
versu imbruvica imbruvica superl drug patient eventu
discontinu atrial fibril bleed therefor better safeti profil import
commerci view
cll data competit versu imbruvica calquenc achiev posit phase result
frontlin r/r cll patient r/r cll set detail phase ascend trial
evalu calquenc monotherapi vs physician choic idelalisib rituximab idr
bendamustin rituximab br present european hematolog associ eha
interim analysi pre-plan event primari event calquenc
show superior idr br reach vs subgroup cll
patient high risk cytogenet statu etc cll calquenc also show
improv idr/br reach vs overal respons rate includ partial
respons lymphocytosi calquenc vs idr/br encouragingli
respons appear durabl median dor reach median overal surviv
reach group median follow-up though patient cross
idr/br diseas progress calquenc arm calquenc appear
better safeti profil idr br combin therapi grade vs idr
br grade neutropenia anemia thrombocytopenia event also seem
line favor idr br notabl atrial fibril seen grade
bleed grade calquenc arm base data calquenc
receiv btd cll suggest competit profil imbruvica
frontlin cll set detail data phase elevate-tn featur
oral present upcom confer abstract abstract show
median reach vs hr median follow-up month calquenc
monotherapi also significantli extend vs gazyva chlorambucil hr median os
reach arm independent-assess respons rate also higher
advers event special interest calquenc gazyva vs calquenc mono vs
gazyva chlorambucil atrial fibril grade vs vs grade bleed
vs vs grade hypertens vs vs view safeti
profil drug appear competit versu imbruvica
believ next-gen btk calquenc brukinsa captur signific
portion market imbruvica well expand address popul b-
cell malign differenti profil calquenc brukinsa
select btk inhibitor demonstr favor safeti toler profil
comparable/bett efficaci b-cell malign accord recent survey btk
inhibitor use cll major clinician note differ calquenc
imbruvica efficaci howev calquenc present moder significantli better
safety/toler imbruvica per survey clinician despit label
calquenc alreadi list compendium use nccn r/r cll astrazeneca
saw calquenc sale come cll indic follow calquenc label
expans grant fda novemb treatment nave r/r cll popul
see set signific opportun clinician potenti switch next-
gener btk inhibitor favor safety/toler profil adopt usag
patient remiss develop toler issu also believ present promis
opportun beigen brukinsa head head data versu imbruvica waldenstrom
expect year end
calquenc could multi-blockbust drug global sale estim
initi launch calquenc mcl pave road cll encouragingli calquenc list
nccn compendium guidelin facilit uptak reimburs ahead recent
obtain formal label expans also encouragingli azn settl ip infring
pharmacycl settlement provis ahead potenti cll commerci launch
estim calquenc sale grow larg
attribut cll launch
exhibit calquenc ww revenu forecast region
calquenc sale region mn
astrazeneca gain access promis
astrazeneca licens ex-japan right daiichi-sankyo up-front
futur mileston captur potenti blockbust target agent
astra daiichi jointli develop monotherapi combin therapi
express cancer like breast gastric colorect lung cancer astra daiichi
co-develop drug co-commerci cost profit split ex-japan territori
strateg global collabor enabl astra expand oncolog space
potenti ad long-term valu astra collabor also allow astra access daiichi
improv technolog highli differenti previou gener
improv linker chemistri potent payload high drug-to-antibodi ratio short system
structur target antibody-drug conjug compos
antibodi amino acid sequenc trastuzumab payload
topoisomeras inhibitor exatecan mesyl deriv bound
topoisomeras inhibitor induc double-strand dna break apoptosi bind
stabil topoisomeras i-dna cleavabl complex preclin studi suggest
potent bystand effect due high membran permeabl payload
penetr neighbor cancer cell compar favor ogitani cancer
demonstr cytotox bystand effect vitro studi wherein payload
affect cell close proxim target cell regardless express
retain compar adcc activ trastuzumab moreov drug-
antibodi ratio therapeut maximum drug load number
convent interchain cystein conjug higher
could potenti increas drug deliveri greater tumor cell kill
unpreced efficaci late line metastat breast gastric cancer
therapi effect breast cancer harbor overexpress and/or
amplif broader spectrum therapi gener good efficaci
recommend standard care posit breast cancer herceptin plu perjeta
docetaxel first-lin therapi metastat breast cancer mbc base
cleopatra trial show median month os month time
diseas progress treatment trastuzumab emtansin recommend
therapi basi improv mpf os tykerb combin
capecitabin emilia trial continu therapi still
recommend patient progress standard care
establish kol suggest re-treat herceptin chemotherapi
primari treatment option consensu regimen set
show promis antitumor activ patient achiev object
respons durabl respons month heavili pretreat mbc patient
median prior therapi phase non-random trial preliminari data
numer favor random trial line therapi
herceptin perjeta chemotherapi safeti patient grade teae lead
discontinu drug relat seriou teae includ interstiti lung diseas ild
pneumon vomit two treatment-rel death due pneumon
preliminari clinic outcom led grant breakthrough therapi design btd
fda treatment mbc bla accept fda octob
grant prioriti review pdufa date set expect detail data
bla submiss pivot phase trial present upcom
sabc decemb
exhibit efficaci metastat breast cancer
therapi progress mbc none approv
breast cancer patient shown preclin tumor kill activ
regardless express initi clinic activ breast cancer
sabc updat data phase trial achiev confirm object
respons durabl respons month median month
respons across breast cancer patient note
antitumor activ also seen hr neg patient previous treat
inhibitor safeti profil consist prior profil see present
attract opportun patient patient
size address patient
exhibit efficaci data metastat breast cancer
overexpress and/or amplif observ gastric cancer patient
cancer herceptin chemotherapi prefer first line therapi improv median
vs os vs chemotherapi alon toga trial patient
metastat gastric cancer progress first-lin treatment challeng treat
fail studi gatsbi trial pembrolizumab rainbow
trial cyramza paclitaxel treatment show clinic meaning outcom significantli
improv median vs os vs vs placebo paclitaxel
group phase trial show encourag initi antitumor activ
manag safeti profil metastat gastric cancer achiev respons rate
os month evalu patient median prior line therapi
exhibit efficaci data gastric cancer
pulmonari toxic overal safety/toler profil manag
consist expect safeti profil use topoisomeras
inhibitor overal incid cardiotox left eject fraction decreas low
treatment-induc pulmonari toxic includ interstiti lung diseas ild
report clinic develop aggreg ild case present sabc
show ild event subject phase studi grade
across clinic studi investig report grade event
preliminari exploratori analysi pool patient ild event like develop
higher dose patient japanes origin though sampl size small action
earli diagnosi steroid moder sever case activ train physician
implement manag ild safeti risk
daiichi/azn build target therapi franchis breast cancer beyond
overexpress describ variou solid tumor includ breast gastric
gastro-esophag junction gej biliari tract colorect bladder non-smal cell lung
cancer incid rang nsclc uterin cancer
preliminari data therapi shown across differ tumor type success
achiev breast cancer agent reproduc gastric
cancer type
exhibit frequenc amplification/overexpression/mut across tumor
daiichi azn build franchis breast cancer
beyond nda applic mbc submit japan regulatori
pathway bla submiss base pivot phase trial
metastat breast cancer detail data present decemb sabc
also phase confirmatori trial vs physician choic tykerb
capecitabin herceptin capecitabin phase head-to-head trial
vs mbc trial on-going also evalu
mbc trial post inhibitor treatment gastric cancer vs chemotherapi
underway expand colorect cancer nsclc
malign tumor overexpression/amplif
geograph diversif emerg market invest
astrazeneca strategi
emerg market em core astrazeneca strategi decad
invest start gener increas valu market evolv opportun
becom tangibl em sale grow annual sinc
outperform rest global market becom azn largest sale region repres
revenu ytd ahead us em sale strong diversifi portfolio
percentag oncolog sale emerg market total oncolog
busi em sale cardiovascular respiratori total sale
exhibit astrazeneca revenu region
china signific part astrazeneca invest thesi emerg market
china sale shown encourag growth compound-annual-growth-rate sinc compris
emerg market sale well compani global revenu strong sale
primarili driven new medicin tagrisso lynparza oncolog brilinta
farxiga cvrm pulmicort nexium symbicort also impress china saw first
approv roxadustat region
exhibit china revenu growth
svb leerink research compani report
china one promis attract market multi-n pharmaceut
compani due overal number patient rapidli age popul strong econom
growth increas access healthcar mani clinic treatment paradigm
formal establish allow legaci new drug gain access
uptak overal pharmaceut market still domin gener china
govern take activ role promot growth innov product
exhibit therapeut area china
azn posit benefit evolv reimburs system china
drug price reimburs polici rapidli evolv china mani market
regulatori approv nation formulari list critic step launch process drug
price base combin free market state control mechan well
provinci price system nation essenti drug list nedl issu everi year
gener drug govern reimburs inclus nation reimburs drug list
nrdl also import nation level nrdl nedl aim make medicin
avail broad group patient nrdl negoti process involv comprehens
submiss manufactur multipl level expert assess recommend
sever month negoti manufactur nation govern drug
price agenc agre reimburs price
exhibit evolv market access landscap china
nrdl list still guarante patient get access drug physician
prescrib drug market need negoti term access patient
assist support individu provinci level take week month
product includ provinci reimburs list sponsor need pull
negoti access import hospit across china
three level nation provinci local level involv increment discount
concess manufactur result increment reduct net realiz price
manufactur discount increas level depend competit
intens categori import note far nation region reimburs
local access confin indic drug formal approv includ line
therapi off-label reimburs china unlik geographi like us
sinc astrazeneca medicin ad nrdl
compani medicin admit nedl sinc nrdl
updat list includ tagrisso approv agent treat second-lin egfr
mutant nsclc tagrisso approv china first-lin treatment
egfrm nsclc nrdl review cycl conclud expect final list
announc immin
trade volum price averag discount nrdl updat
oncolog drug compar china privat market list price recent
adopt medicin nrdl list see averag discount versu us list price wac
basi across oncolog cvrm respiratori therapeut area note huge
price discrep china us cautiou drug us
lost exclus crestor gener drug lower price avail us
market list price drug us complet transpar
rebat incent often result net discount high single-digit mid-teen
establish compani advantag commerci drug china also
complic afford compani experi infrastructur competit
advantag market particip need master tradit activ widespread
distribut medic educ consum awar physician promot well
complex activ nation region local reimburs list mani
manufactur scale organ requir accomplish activ effect
china like larg larger commerci organ us although
lower cost per employe basi also govern polici inevit go
consider impact commerci success
believ astrazeneca well-posit employe china multipl
collabor govern see strong launch new medicin tagrisso
lynparza oncolog continu revenu growth brilinta farxiga cvrm
pulmicort symbicort despit signific gener eros crestor us eu japan
crestor sale china still deliv expect crestor
sale declin yoy mainli due increas price pressur gener medicin
failur make volume-bas purchas pilot tender list pilot tender list part
govern new drug price procur reform provid framework
bid process drug procur four municip beij shanghai tianjin
chongq citi guangzhou shenzhen xian dalian chengdu xiamen
exhibit bid process drug procur reform
nevertheless believ strong launch new medicin tagrisso lynparza
continu fuel strong growth china valid market support innov
exhibit price discount public reimburs china
note formulari placement result price discount compani longer
suppli free drug offset net impact significantli
exhibit select astrazeneca nrdl drug price china vs us wac price
exhibit complet nrdl list astrazeneca medicin
azn also directli invest drug develop china
astrazeneca demonstr capabl develop drug china via differ strategi
recent compani partner local industri fund invest research
collabor innov healthcar compani well intern compani look
establish presenc china astrazeneca also recent sign agreement sun pharma
bring innov medicin china azn prolif collabor local player
includ partnership chi-m evalu combin savolitinib inhibitor
tagrisso potenti address resist aris amplif follow treatment
tagrisso astrazeneca collabor develop roxadustat china
obtain first global approv drug china ahead region
commerci side astrazeneca obtain solo commerci right constip drug linzess
china follow chines regulatori approv januari addit azn establish
numer collabor local contract research organ streamlin
compani earli preclin research program overal see astrazeneca well posit
china strong commerci product sale strateg collabor demonstr long-
term commit region
companyprogram/drugtherapeut areaeventtimingev typetri phaseastrazenecacalquencechron lymphocyt leukemiaphas elevate-tn data calquenc gazyva vs gazyva chlorambucil frontlin cll trial dataphazn/fgenroxadustatmd anemia phase data roxadustat mds-relat trial breast cancerphas trial trastuzumab deruxtecan data metastat breast cancer trial dataphazn/fgenroxadustatanemia ckdregulatori submiss fda roxadustat chronic kidney diseas ckd stage regulatori decis imfinzi stage nsclc pacif submiss symbicort mild cancerregulatori decis lynparza brcam ovarian cancer cancerfda decis lynparza brcam pancreat cancer aspen trial brukinsa r/r waldenstrom macroglobulinemia vs trial dataphastrazenecaimfinzisclcpotenti fda submission/accept imfinzi sclc trial keytruda extensive-stag trial dataphgsk zejulaovarian cancersnda submiss ph prima trial zejula ovarian cancer cancersnda submiss lynparza broad ovarian cancer mainten gastric cancerphas data trastuzumab deruxtecan gastric trial dataphiiazn/mrklynparzaovarian cancerphas data cediranib lynparza lynparza/ chemo recurr platinum sensit ovarian trial dataphastrazenecaimfinzibladd cancerdata phase danub imfinzi treme/imfinzi/soc bladder trial dataphastrazenecafarxigadiabetesregulatori submiss accept hfref base dapa-hf cancerphas bayou data imfinzi lynparza vs imfinzi trial dataphastrazenecaimfinzihead neck cancerphas kestrel data imfinzi/ imfinzi treme/ soc head neck trial dataphastrazenecabrilintastrokephas thale brilinta vs placebo acut ischaem stroke transient ischaem clinic trial dataphastrazenecacalquencechron lymphocyt leukemiapotenti fda approv calquenc regulatoryn/aazn/mrkselumetinibpediatr approv selumetinib pediatr neurofibromatosi type pdufa date breast cancerpotenti approv metastat breast regulatori submission/accept brilinta base thale trial begonia trial imfinzi paclitaxel mtnbc trial dataphastrazenecaimfinzinsclcphas aegean imfinzi chemo data neoadjuv stage resect nsclc trial dataphastrazenecaimfinzinsclcphas imfinzi chemort vs placebo chemort data unresect locally-advanc trial dataphastrazenecaepanovahypertriglyceridaemiaphas strength data epanova statin patient hypertriglyceridaemia high cardiovascular increas risk trial denali mild moder trial dataphastrazenecafasenraasthmaphas meltemi ponent trial asthmat adult ic plu agonist trial dataphastrazenecafasenranas polyposisdata phase ostro sever bilater nasal trial dataphastrazenecatezepelumabasthmadata phase navig trial sever trial dataphastrazenecaanifrolumablupuspotenti regulatori file anifrolumab moder -to-sever lupu nsclcphase data trastuzumab deruxtecan mutat trial dataphastrazenecaimfinzi tremensclcdata ph poseidon trial nsclc imfinzi chemo vs imfinzi treme chemo vs chemo trial dataphgsk zejulaovarian cancerdata zejula platinum-resist ovarian cancer phii oncologyrubracaovarian cancerdata ph athena studi rubraca/opdivo ovarian cancer mainten per compani trial dataphastrazenecaimfinzi tremehccphas himalaya data imfinzi treme vs imfinzi vs sorafenib trial dataphastrazenecaimfinzi tremesclcphas adriat data imfinzi treme data limit disease-sclc post trial breast cancerphas data trastuzumab deruxtecan breast trial breast cancerphas trial data trastuzumab deruxtecan vs breast trial breast cancerphas trial data vs investig choic int/low breast trial dataphastrazenecaimfinzi tremesclcphas adriat trial imfinzi treme data limit disease-sclc post trial dataphastrazenecaimfinzinsclcphas pearl asian trial trial data trial dataphastrazenecaimfinzisclcphas baltic data imfinzi treme /advosertib trial dataphiiastrazenecaimfinzibladd cancerphas nile data imfinzi treme soc/imfinzi soc /soc bladder trial dataphastrazenecatagrissonsclc phase laura trial data tagrisso mainten therapi unresect egfrm stage trial data phazn/mrkimfinzi lynparzaovarian cancerphas duo-o trial data imfinzi/lynparza/bev/chemo combo non-brcam ovarian cancer trial dataphastrazenecatagrissonsclcphas adaura trial data tagrisso adjuv egfrm nsclc trial data phastrazenecatagrissonsclc phase trial data tagrisso chemo combo egfrm trial data phastrazeneca catalyst astrazeneca plc
astrazeneca mn except ep
sale
net loss attribut non-controlling interest
net incom loss attribut azn
svb leerink estim compani file
cash equival
trade receiv
short-term borrow overdraft
trade payabl
total liabil sharehold equiti
oper profit tax
depreci amort impair
increas work capit
incl profit sale subsidiari
net cash oper activ
movement short-term invest fix deposit
purchas pp other
purchases/dispos other
net cash use invest activ
proce issuanc share capit
net cash provid use financ
net increas cash cash equival
cash equival begin period
cash equival end period
report cash equival
adjust cash equival
svb leerink estim compani file
